We next examined T-cell immunity in the IL-33- and GM-CSF-treated TB mice and found that the frequency of effector CD8+ cells in the spleen and CTL activity in tumor-infiltrating lymphocytes (TILs) increased significantly in the IL-33-treated mice but not the GM-CSF-treated mice (Fig. 2D-E). The gene discussed is IL33; the disease is neoplasm.